• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Nutex Health (NUTX) Undervalued On Its Nasdaq Texas Dual Listing Approval?

    Simply Wall St·09/24/2026 10:29:45
    Listen to the news

    Nutex Health (NUTX) received approval to dual list its common stock on Nasdaq Texas, with trading expected to begin around 23 September 2026. This move could reshape liquidity and investor reach.

    For investors tracking Nutex Health, the Nasdaq Texas approval lands after a mixed near term stretch where the share price fell 3.33% over the past day and 5.81% over the past week, yet still shows a 30 day share price return of 7.32% and a 90 day move of 21.31%. Year to date share price gains of 36.22% sit alongside a 1 year total shareholder return of 107.95% and a 3 year total shareholder return of nearly 6x, suggesting recent weakness comes after a strong run and that sentiment around liquidity and risk has been shifting over multiple timeframes.

    Scan beyond Nutex Health and review other hospital and healthcare operators that appear strong on balance sheets and fundamentals using our curated list of solid balance sheet and fundamentals (23 results).

    For Nutex Health, that split between shorter term weakness and longer term strength now coincides with a fresh listing venue and new attention from investors. Are investors reassessing the fundamentals, or simply rerating the story based on sentiment and liquidity as the dual listing approaches?

    Most Popular Narrative: 29% Undervalued

    Nutex Health closed at $201.86, while the most widely followed narrative pegs fair value at $283. This gap puts the dual listing into a very real question for investors, who now need to weigh liquidity benefits against what the narrative suggests about long term cash flows and risk.

    The continued shift toward consumer-driven and ambulatory care is expanding Nutex Health's addressable market. Their micro-hospital and freestanding ER model aligns with preferences for convenient, efficient care, which supports enhanced market share and greater revenue per visit over time.

    The company's navigation of value-based care and risk-based contracts, including expansion of IPAs and population health management capabilities, is described as positioning it to benefit from industry reimbursement trends, with the potential to affect margins and recurring earnings as the model develops.

    See why 19 investors see Nutex Health as 29% undervalued.

    Result: Fair Value of $283 (UNDERVALUED)

    Still, the narrative around Nutex Health could be challenged if arbitration driven revenue faces tougher regulation, or if new facility openings fail to deliver expected volume.

    Find out about the key risks to this Nutex Health narrative.

    Next Steps

    Mixed signals around Nutex Health can easily pull you in both directions, so move quickly and pressure test the story against your own judgement by reviewing the 4 key rewards and 3 important warning signs.

    Looking for more Nutex Health sized opportunities?

    If Nutex Health has your attention, do not stop here. Cast the net wider and let data driven stock ideas shape your next move.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.